Effectiveness of Nicotine Withdrawal Symptoms Management Program Using LINE Application to Increase Self-Efficacy for Industrial Workers

2021 ◽  
Vol 104 (12) ◽  
pp. 1920-1929
Keyword(s):  
Smoking Cessation ◽  
Self Efficacy ◽  
Nicotine Withdrawal ◽  
Management Program ◽  
Withdrawal Symptoms ◽  
Control Group ◽  
Industrial Workers ◽  
Exhaled Carbon Monoxide ◽  
Cigarette Craving ◽  
Withdrawal Management

Background: Smoking is a risk factor for chronic diseases. A combination of tobacco use with occupational hazards among industrial workers could increase the risk of occupational disease and injury. Nicotine is known to be highly addictive. It is difficult not only to maintain the decrease in smoking but also to continue quitting tobacco use. Moreover, nicotine withdrawal can be challenging and lead to failure in the smoking cessation process. Self-efficacy theory has been used recently for the development of effective smoking cessation programs. Objective: To develop an online nicotine withdrawal symptoms management program based on self-efficacy theory and examine its effectiveness. Materials and Methods: A quasi-experimental design with a control group pretest-posttest design was used. The sample consisted of male employees working in a consumer product manufacturing industry in Bangkok. An intervention group (n=28) received an online nicotine withdrawal symptoms management program via LINE application based on self-efficacy theory for one month. In comparison, participants in the control group (n=29) received a conventional smoking cessation program. The effectiveness of the intervention on nicotine withdrawal symptoms, cigarette craving, self-efficacy perception of nicotine withdrawal management, cigarette rolls per day, nicotine dependence level, exhaled carbon monoxide level, and smoking cessation behavior the first and fourth week were examined using a repeated-measures analysis of variance. Results: At one-month follow-up, there were significant differences between the two groups on nicotine withdrawal symptoms score, cigarette craving level, self-efficacy perception of nicotine withdrawal management, cigarette rolls per day, nicotine addiction level, exhaled carbon monoxide level, and smoking cessation behaviors (p<0.001). In addition, there was a significant difference in the self-reported nicotine withdrawal symptoms score in terms of irritability, anger, anxiety, concentration deficit, depression, and insomnia (p<0.001) between groups, between times, and between times and groups (p<0.001). Conclusion: Nicotine withdrawal symptoms management program using LINE application is effective in encouraging smoking cessation. Keywords: Smoking cessation; Nicotine withdrawal symptoms; LINE application; Industrial workers

Nicotine and Tobacco

2020 ◽  
pp. 149-182
Author(s):  
Shadi Nahvi ◽  
Darius A. Rastegar
Keyword(s):  
Cardiovascular Disease ◽  
Carbon Monoxide ◽  
Smoking Cessation ◽  
Lung Disease ◽  
Tobacco Use ◽  
Chronic Lung Disease ◽  
Electronic Cigarettes ◽  
Withdrawal Symptoms ◽  
Tobacco Products ◽  
Exhaled Carbon Monoxide

Nicotine is responsible for the psychoactive and habit-forming effects of tobacco. Approximately 30% of Americans use tobacco products; half of them are nicotine-dependent. Nicotine has mild stimulant effects. Overdose is rare in experienced users. Some may develop nausea, vomiting, weakness, and dizziness. Withdrawal symptoms include craving, irritability, anxiety, restlessness, and increased appetite. Smokers have elevated exhaled carbon monoxide and serum carboxyhemoglobin levels. Cotinine, a metabolite of nicotine, can be detected in blood and urine. Many medical conditions are associated with tobacco use (particularly smoking), including cardiovascular disease, chronic lung disease, and a variety of malignancies. A number of interventions can help increase smoking cessation rates, including physician advice, counseling, nicotine replacement, varenicline, and bupropion. Electronic cigarettes may help smokers quit or reduce their smoking.

scholarly journals Activation of AMPK by metformin improves withdrawal signs precipitated by nicotine withdrawal

2018 ◽  
Vol 115 (16) ◽  
pp. 4282-4287 ◽  
Author(s):  
Julia K. Brynildsen ◽  
Bridgin G. Lee ◽  
Isaac J. Perron ◽  
Sunghee Jin ◽  
Sangwon F. Kim ◽  
...  
Keyword(s):  
United States ◽  
Smoking Cessation ◽  
The United States ◽  
Nicotine Withdrawal ◽  
Withdrawal Symptoms ◽  
Ampk Activation ◽  
Ampk Signaling ◽  
Amp Activated Protein Kinase ◽  
Multiple Health ◽  
Withdrawal Signs

Cigarette smoking is the leading cause of preventable disease and death in the United States, with more persons dying from nicotine addiction than any other preventable cause of death. Even though smoking cessation incurs multiple health benefits, the abstinence rate remains low with current medications. Here we show that the AMP-activated protein kinase (AMPK) pathway in the hippocampus is activated following chronic nicotine use, an effect that is rapidly reversed by nicotine withdrawal. Increasing pAMPK levels and, consequently, downstream AMPK signaling pharmacologically attenuate anxiety-like behavior following nicotine withdrawal. We show that metformin, a known AMPK activator in the periphery, reduces withdrawal symptoms through a mechanism dependent on the presence of the AMPKα subunits within the hippocampus. This study provides evidence of a direct effect of AMPK modulation on nicotine withdrawal symptoms and suggests central AMPK activation as a therapeutic target for smoking cessation.

Reduction of anxiety sensitivity in relation to nicotine withdrawal symptoms during smoking cessation: an examination among successful quitters

2017 ◽  
Vol 47 (4) ◽  
pp. 301-314 ◽  
Author(s):  
Jafar Bakhshaie ◽  
Michael J. Zvolensky ◽  
Kirsten J. Langdon ◽  
Adam M. Leventhal ◽  
Norman B. Schmidt
Keyword(s):  
Smoking Cessation ◽  
Anxiety Sensitivity ◽  
Nicotine Withdrawal ◽  
Withdrawal Symptoms

scholarly journals Efficacy of an Internet-based, individually tailored smoking cessation program: A randomized-controlled trial

2016 ◽  
Vol 23 (5) ◽  
pp. 521-528 ◽  
Author(s):  
Céline Mavrot ◽  
Iris Stucki ◽  
Fritz Sager ◽  
Jean-François Etter
Keyword(s):  
Randomized Controlled Trial ◽  
Smoking Cessation ◽  
Self Efficacy ◽  
Controlled Trial ◽  
Control Group ◽  
Randomized Controlled ◽  
Motivation To Quit ◽  
Computer Based ◽  
E Mail ◽  
Tailored Program

Introduction Self-help computer-based programs are easily accessible and cost-effective interventions with a great recruitment potential. However, each program is different and results of meta-analyses may not apply to each new program; therefore, evaluations of new programs are warranted. The aim of this study was to assess the marginal efficacy of a computer-based, individually tailored program (the Coach) over and above the use of a comprehensive Internet smoking cessation website. Methods A two-group randomized controlled trial was conducted. The control group only accessed the website, whereas the intervention group received the Coach in addition. Follow-up was conducted by e-mail after three and six months (self-administrated questionnaires). Of 1120 participants, 579 (51.7%) responded after three months and 436 (38.9%) after six months. The primary outcome was self-reported smoking abstinence over four weeks. Results Counting dropouts as smokers, there were no statistically significant differences between intervention and control groups in smoking cessation rates after three months (20.2% vs. 17.5%, p = 0.25, odds ratio (OR) = 1.20) and six months (17% vs. 15.5%, p = 0.52, OR = 1.12). Excluding dropouts from the analysis, there were statistically significant differences after three months (42% vs. 31.6%, p = 0.01, OR = 1.57), but not after six months (46.1% vs. 37.8%, p = 0.081, OR = 1.41). The program also significantly increased motivation to quit after three months and self-efficacy after three and six months. Discussion An individually tailored program delivered via the Internet and by e-mail in addition to a smoking cessation website did not significantly increase smoking cessation rates, but it increased motivation to quit and self-efficacy.

scholarly journals Effect of Self-Management Program on Self-efficacy and Medication Adherence in Patients with Mechanical Heart Valve: a Randomized Clinical Trial

2019 ◽  
Vol 8 (4) ◽  
pp. 207-211
Author(s):  
Leila Javan ◽  
Aanoshirvan Kazemnejad ◽  
Mahin Nomali ◽  
Maasumeh Zakerimoghadam
Keyword(s):  
Medication Adherence ◽  
Heart Valve ◽  
Self Efficacy ◽  
Controlled Trial ◽  
Mechanical Heart Valve ◽  
International Normalized Ratio ◽  
Management Program ◽  
Self Management ◽  
Control Group ◽  
Replacement Surgery

Introduction: Patients with mechanical heart valve need anticoagulant therapy to prevent thrombotic events. The treatment interacts with some foods and drugs. The aim was to evaluate the effect of self- management program on self-efficacy and medication adherence in patients with mechanical heart valve. Methods: This was a randomized controlled trial. eighty eligible patients, with the ability to read and speak in Farsi, aged between 15 to 60, were included in the study from the cardiac surgery clinic in Imam Khomeini hospital affiliated to Tehran University of Medical Sciences (Tehran, Iran) and randomly allocated to intervention and control groups. The participants had no history of psychiatric disorders, had undergone valve replacement surgery at least one year before the study, and were being treated with Warfarin. The intervention was a combination of 2 one- hour selfmanagement education via small groups with 3 to 5 members, self-management educational booklets, and weekly call follow- ups for 8 weeks about 10- 15 minutes. The control group received no intervention. Self- efficacy was the primary outcome and medication adherence, Prothrombin Time (PT), and International Normalized Ratio (INR) were secondary outcomes. Data were analyzed using SPSS13. Results: Although the mean of self-efficacy and medication adherence, PT, and INR values were not different between the two groups at baseline, they improved significantly following the program. Conclusion: Self-management program had a positive effect on self-efficacy and medication adherence of patients with mechanical heart valve.

Engaging Adults With Chronic Disease in Online Depressive Symptom Self-Management

2017 ◽  
Vol 40 (6) ◽  
pp. 834-853 ◽  
Author(s):  
Marian Wilson ◽  
Casey Hewes ◽  
Celestina Barbosa-Leiker ◽  
Anne Mason ◽  
Katherine A. Wuestney ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Chronic Disease ◽  
Treatment Group ◽  
Self Efficacy ◽  
Management Program ◽  
Self Management ◽  
Control Group ◽  
Number Needed To Treat ◽  
Participant Engagement ◽  
Patient Health

The main purpose of this study was to evaluate participant engagement and effects of an Internet-based, self-directed program for depressive symptoms piloted among adults with a chronic disease. Eligible participants ( N = 47) were randomly assigned to either the “Think Clearly About Depression” online depression self-management program or the control group. The Patient Health Questionnaire–8 and Chronic Disease Self-Efficacy Scales were administered at baseline and at Weeks 4 and 8 after initiating the intervention. Number Needed to Treat analysis indicated that one in every three treatment group participants found clinically significant reductions in depressive symptoms by Week 8. Paired-sample t tests showed that depressive symptoms and self-efficacy in management of depressive symptoms improved over time for those in the treatment group and not for those in the control group. Participants’ engagement and satisfaction with the online program were favorable.

scholarly journals The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e038184
Author(s):  
Rukshar Kaizerali Gobarani ◽  
Michael J Abramson ◽  
Billie Bonevski ◽  
Gregory R Weeks ◽  
Michael J Dooley ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Controlled Trial ◽  
Intervention Group ◽  
Ethics Committees ◽  
Good Clinical Practice ◽  
Withdrawal Symptoms ◽  
Responsible Conduct Of Research ◽  
Control Group ◽  
Efficacy And Safety ◽  
Success Rates

IntroductionSmoking is a leading cause of premature deaths globally. The health benefits of smoking cessation are many. However, majority of quit attempts are unsuccessful. One way to potentially improve success rates is to evaluate new combinations of existing smoking cessation therapies that may work synergistically to decrease the intensity of withdrawal symptoms and cravings.AimsTo evaluate the feasibility, efficacy and safety of the combination of varenicline and nicotine replacement therapy (NRT) lozenges versus varenicline alone in assisting hospitalised smokers to quit.Methods and analysisThis is a multicentre, randomised, placebo-controlled trial. Adults with a history of smoking ≥10 cigarettes per day on average in the 4 weeks prior to their hospitalisation will be recruited. Participants will be randomly assigned to either the intervention group and will receive varenicline and NRT lozenges, or the control group and will receive varenicline and placebo lozenges. All participants will be actively referred to behavioural support from telephone Quitline. Participants are followed up at 1 and 3 weeks and 3, 6 and 12 months from the start of treatment. The primary outcome is carbon monoxide validated prolonged abstinence from 2 weeks to 6 months after treatment initiation. Secondary outcomes include self-reported and biochemically validated prolonged and point prevalence abstinence at 3, 6 and 12 months, self-reported adverse events, withdrawal symptoms and cravings, adherence to treatment, Quitline sessions attended and others. According to the Russell Standard, all randomised participants will be accounted for in the primary intention-to-treat analysis.Ethics and disseminationThe trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice, the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for the Responsible Conduct of Research (2018). Approval will be sought from the Human Ethics Committees of all the participating hospitals and the university. Written informed consent will be obtained from each participant at the time of recruitment.Trial registration numberAustralia New Zealand Clinical Trials Registry (ACTRN12618001792213).

scholarly journals A Randomised Controlled Trial Evaluating the Effectiveness and Tolerability of Step-up and Step-down Varenicline Therapy for Smoking Cessation: A Study Protocol

2017 ◽  
Vol 13 (3) ◽  
pp. 179-185
Author(s):  
Aaron D. Drovandi ◽  
Peta-Ann Teague ◽  
Beverley D. Glass ◽  
Bunmi Malau-Aduli
Keyword(s):  
Smoking Cessation ◽  
Adverse Events ◽  
Outcome Measures ◽  
Controlled Trial ◽  
Intervention Group ◽  
Withdrawal Symptoms ◽  
Secondary Outcome ◽  
Control Group ◽  
Step Down

Background: Varenicline remains the most effective medication for smoking cessation; however, discontinuation as a result of adverse events negatively impacts medication adherence, and the likelihood of a quit attempt being successful. Post-treatment cravings and withdrawal symptoms may also occur, increasing the likelihood of treatment failure, due to lapse and relapse after achieving initial abstinence. This protocol details a trial investigating changes in the effectiveness and tolerability of varenicline, when an extended step-up and step-down regimen are used.Methods: A phase four, randomised, double-blinded, placebo-controlled single-centre study with a treatment period of 16 weeks, and follow-up period of 12 weeks will be conducted. Up to 201 participants will be enrolled and allocated in a 1:1:1 ratio to a placebo-matching control group, step-up, or step-down intervention group, all receiving behavioural counselling and quitting advice. Participants will be contacted weekly during treatment and fortnightly during follow-up. Eligible participants are smokers over 18 years old, willing to quit smoking, are able to attend clinic visits, and have no uncontrolled or serious medical issues. Primary outcome measures are comparisons of biochemically confirmed continuous abstinence rates, 7-day point prevalence abstinence rates, and the frequency, severity and duration of adverse events, cravings and withdrawal symptoms. Secondary outcome measures are participant adherence to the study medication throughout treatment, and comparisons of changes in smoking satisfaction and reward. Effects of each regimen on smoking cessation will be assessed by logistic regression, with survival analyses used for a more precise estimate of when cessation occurs. Primary endpoints will then be compared using a general linear model. Australian New Zealand Clinical Trials Registry: ACTRN12616000802404p

scholarly journals Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment

2011 ◽  
Vol 36 (1-2) ◽  
pp. 144-147 ◽  
Author(s):  
Robert A. Schnoll ◽  
Elisa Martinez ◽  
Kristina L. Tatum ◽  
Marcella Glass ◽  
Albert Bernath ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Nicotine Dependence ◽  
Perceived Control ◽  
Self Efficacy ◽  
Withdrawal Symptoms
Sign in / Sign up

Export Citation Format

Share Document